This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cardinal Health's CEO Discusses Q3 2012 Results - Earnings Call Transcript

I'd like to walk you through the performance highlights of these segments. First, Pharmaceutical. Revenue increases came from multiple classes of trade. This growth outpaced the market in virtually every channel. Our focus on creating value for the specific needs of each customer in this dynamic environment remains a top priority. Our customer base remains strong, and the mix continues to evolve along our strategic pathway. Our non-bulk sales were up 7.6% versus prior year.

Profit was fueled by the continued strength of our generic activities and solid performance with our branded partners, whose names continue to evolve in changing markets. Our strong generic results reflect the continued focus in this important industry driver and the impact of new and recently launched products, a number of which launched in the prior quarter.

I want to take a few moments to comment on our nuclear activities, as this part of the industry has been going through some change. We see distinct market dynamics at work from the 2 different nuclear product lines. On the low energy side, our legacy business, demand remains soft. Although we continue to provide market-leading products and the supply of raw materials to us has been reliable, the number of nuclear cardiac procedures is considerably below historical norms.

Part of this can be explained by general economic conditions and part is likely associated with payer and employer policies designed to continue growth in medical procedures. We've been making the necessary modification to our business to adjust to what maybe the new normal from a cardiac-procedure perspective. I should note here that demographics should, in the long-term, generate some upward pressure on demand.

As you know, our activities in the PET area are at a different stage of evolution. We were excited to see the FDA approval of Amyvid and high-energy products used in PET scanning as a diagnostic product for patients being evaluated for Alzheimer's reviews. We have been an innovator in this area, a partner in the development of this product, and we will be an important part of the team as the manufacturer and distributor of Amyvid from our specialized facilities.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.82 -0.45%
FB $118.57 0.65%
GOOG $706.50 0.72%
TSLA $211.72 0.09%
YHOO $36.82 -0.32%


Chart of I:DJI
DOW 17,625.75 -34.96 -0.20%
S&P 500 2,041.56 -9.07 -0.44%
NASDAQ 4,689.3940 -27.70 -0.59%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs